TY - JOUR
T1 - The Impact of an Antithrombotic Stewardship Program on Heparin-Induced Thrombocytopenia Management
AU - Lee, John
AU - Lindsley, John
AU - Chasler, Jessica
AU - Streiff, Michael B.
AU - Naik, Rakhi
AU - Shanbhag, Satish
AU - Dane, Kathryn E.
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2023/12
Y1 - 2023/12
N2 - Background: An antithrombotic stewardship program was implemented to reduce IV DTI use and increase fondaparinux and direct oral anticoagulant (DOAC) use for suspected or confirmed Heparin-induced thrombocytopenia (HIT). Objectives: This study evaluated the impact of an antithrombotic stewardship program on IV DTI utilization in patients with HIT. Methods: A retrospective analysis of adults receiving IV DTIs or fondaparinux from July 2016 to July 2017 (pre-stewardship) and October 2017 to July 2019 (post-stewardship) was conducted. Results: The median duration of IV DTI administration was not significantly different in HIT-negative patients between the pre- and post-stewardship cohorts (1.6 days (25th percentile (p25), 75th percentile (p75):.5, 3.3) vs 1.7 days (p25, p75:.9, 3.9), P =.31). The median duration of IV DTI administration in HIT-positive patients was 9.9 days (p25, p75: 7.6, 21.0) pre-stewardship and 7.3 days (p25, p75: 4.8, 16.5) post-stewardship (P =.18). For HIT-positive patients, the time from HIT diagnosis to discharge was 12.8 days (p25, p75: 8.9, 24.9) and 9.2 days (p25, p75: 4.0, 18.1) in the pre- and post-stewardship cohorts, respectively (P =.07). Fondaparinux and DOAC prescribing rates were 40.7% and 62.2% in the pre- and post-stewardship cohorts, respectively (P =.09). The percentage of patients with no contraindications to IV DTI alternatives receiving these agents increased from 31.2% to 78.6% (P =.01) following stewardship implementation. Conclusions: Intravenous DTI alternative utilization increased significantly after stewardship implementation. Stewardship implementation was associated with a non-statistically significant trend towards decreased IV DTI utilization and decreased length of stay for HIT-positive patients.
AB - Background: An antithrombotic stewardship program was implemented to reduce IV DTI use and increase fondaparinux and direct oral anticoagulant (DOAC) use for suspected or confirmed Heparin-induced thrombocytopenia (HIT). Objectives: This study evaluated the impact of an antithrombotic stewardship program on IV DTI utilization in patients with HIT. Methods: A retrospective analysis of adults receiving IV DTIs or fondaparinux from July 2016 to July 2017 (pre-stewardship) and October 2017 to July 2019 (post-stewardship) was conducted. Results: The median duration of IV DTI administration was not significantly different in HIT-negative patients between the pre- and post-stewardship cohorts (1.6 days (25th percentile (p25), 75th percentile (p75):.5, 3.3) vs 1.7 days (p25, p75:.9, 3.9), P =.31). The median duration of IV DTI administration in HIT-positive patients was 9.9 days (p25, p75: 7.6, 21.0) pre-stewardship and 7.3 days (p25, p75: 4.8, 16.5) post-stewardship (P =.18). For HIT-positive patients, the time from HIT diagnosis to discharge was 12.8 days (p25, p75: 8.9, 24.9) and 9.2 days (p25, p75: 4.0, 18.1) in the pre- and post-stewardship cohorts, respectively (P =.07). Fondaparinux and DOAC prescribing rates were 40.7% and 62.2% in the pre- and post-stewardship cohorts, respectively (P =.09). The percentage of patients with no contraindications to IV DTI alternatives receiving these agents increased from 31.2% to 78.6% (P =.01) following stewardship implementation. Conclusions: Intravenous DTI alternative utilization increased significantly after stewardship implementation. Stewardship implementation was associated with a non-statistically significant trend towards decreased IV DTI utilization and decreased length of stay for HIT-positive patients.
KW - antithrombotic stewardship
KW - direct oral anticoagulant
KW - direct thrombin inhibitors
KW - fondaparinux
KW - heparin induced thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=85134420884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134420884&partnerID=8YFLogxK
U2 - 10.1177/08971900221116185
DO - 10.1177/08971900221116185
M3 - Article
C2 - 35848327
AN - SCOPUS:85134420884
SN - 0897-1900
VL - 36
SP - 1343
EP - 1349
JO - Journal of Pharmacy Practice
JF - Journal of Pharmacy Practice
IS - 6
ER -